|
Number
|
49
|
27
|
76
|
–
|
|
Age (years)
|
73 (62–78)
|
70 (61–78)
|
71 (61–78)
|
0.765
|
|
Male, n (%)
|
22 (44.9 %)
|
15 (55.6 %)
|
37 (48.7 %)
|
0.792
|
|
WBC (×109/L)
|
14.9 (12.4–16.9)
|
13.3 (10.9–17.8)
|
14.9 (11.8–17.2)
|
0.641
|
|
Lymphocyte (×109/L)
|
0.78 (0.59–1.24)
|
0.65 (0.52–0.82)
|
0.76 (0.54–1.07)
|
0.046
|
|
SOFA score
|
11 (9–12)
|
14 (12–17)
|
11 (9–14)
|
<0.001
|
|
SAPS II
|
50 (43–56)
|
60 (53–66)
|
53 (46–60)
|
<0.001
|
|
Percentage of PD-1+/CD4+ T cells (%)
|
35.1 (28.5–44.8)
|
42.9 (34.9–49.0)
|
38.2 (29.2–47.7)
|
0.034
|
|
MFI of PD-1 on CD4+ T cells
|
7.0 (5.7–8.9)
|
8.8 (7.1–9.6)
|
7.5 (6.0–9.4)
|
0.036
|
|
Percentage of PD-1+/CD8+ T cells (%)
|
33.0 (24.8–44.3)
|
47.1 (30.3–53.9)
|
36.5 (27.3–51.3)
|
0.032
|
|
MFI of PD-1 on CD8+ T cells
|
5.9 (4.7–8.1)
|
7.8 (5.4–9.8)
|
6.6 (4.9–8.4)
|
0.033
|
|
Percentage of PD-L1+/CD4+ T cells (%)
|
16.4 (8.6–28.4)
|
22.1 (12.0–34.0)
|
21.0 (9.3–30.6)
|
0.295
|
|
MFI of PD-L1 on CD4+ T cells
|
1.9 (1.5–2.0)
|
1.8 (1.6–2.2)
|
1.8 (1.5–2.0)
|
0.961
|
|
Percentage of PD-L1+/CD8+ T cells (%)
|
23.2 (10.8–38.9)
|
12.9 (9.9–32.5)
|
19.5 (10.3–37.4)
|
0.204
|
|
MFI of PD-L1 on CD8+ T cells
|
1.6 (1.4–1.9)
|
1.5 (1.4–1.7)
|
1.5 (1.4–1.8)
|
0.378
|
|
Percentage of monocytes expressing PD-L1 (%)
|
28.9 (17.9–43.6)
|
53.9 (31.8–72.9)
|
35.9 (20.4–54.7)
|
0.001
|
|
MFI of PD-L1 on monocytes
|
8.2 (7.5–9.0)
|
9.1 (8.1–11.3)
|
8.3 (7.7–9.7)
|
0.012
|
|
Type of infection, n (%)
| | | |
|
Pneumonia
|
27 (55.1 %)
|
14 (51.9 %)
|
41 (53.9 %)
|
0.786
|
|
IAI
|
8 (16.3 %)
|
3 (11.1 %)
|
11 (14.5 %)
|
0.781
|
|
CNSI
|
4 (8.2 %)
|
2 (7.4 %)
|
6 (7.9 %)
|
0.743
|
|
USI
|
10 (20.4 %)
|
8 (29.6 %)
|
18 (23.7 %)
|
0.366
|
|
Number of comorbidities
| | | |
|
≥1, n (%)
|
21 (42.9 %)
|
18 (66.7 %)
|
39 (51.3 %)
|
0.047
|
